Sandoz Group AG (SWX:SDZ)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 23.04B |
| Revenue (ttm) | 8.42B |
| Net Income (ttm) | 180.53M |
| Shares Out | 430.70M |
| EPS (ttm) | 0.42 |
| PE Ratio | 128.65 |
| Forward PE | 18.05 |
| Dividend | 0.60 (1.12%) |
| Ex-Dividend Date | Apr 17, 2025 |
| Volume | 791,141 |
| Average Volume | 717,416 |
| Open | 54.08 |
| Previous Close | 53.50 |
| Day's Range | 53.90 - 55.66 |
| 52-Week Range | 26.25 - 55.66 |
| Beta | 0.27 |
| RSI | 77.51 |
| Earnings Date | Oct 30, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileNews
SDZNY vs. STVN: Which Stock Is the Better Value Option?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Sandoz Group AG (SDZNY) Q3 2025 Sales Call Transcript
Sandoz Group AG (SDZNY) Q3 2025 Sales/ Trading Statement Call - Slideshow
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
Sandoz granted tentative approval for generic of Pfizer's Inlyta
Sandoz gets FDA tentative approval for a generic of Pfizer’s kidney cancer drug Inlyta, but launch is delayed by patent litigation. Read more here.
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Sandoz welcomes Quebec government support for Boucherville plant modernization project
Sandoz underlines importance of Delpharm Boucherville plant modernization project, made possible by total investment of CAD 220 million Amount includes joint investments from provincial and federal go...
Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets
Lupin Limited announced on August 12 that it has entered into a licensing and commercialization agreement with Switzerland-based Sandoz Group AG for its biosimilar Ranibizumab. The deal covers multipl...
Sandoz Group AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Sandoz Group AG in conjunction with their 2025 Q2 earnings call.
Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
Danish pharma giant Novo Nordisk A/S (NYSE: NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a ...
Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...
Amgen faces antitrust lawsuit from Sandoz over Enbrel patents
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News
Novartis After Sandoz: The Business Without Generics
Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions
La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...
Sandoz: Upgrading To A Buy On 2028 Expectations
Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE
BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives
US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.